gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Chemotherapy induced nausea and vomitus (CINV) depends on pharmacogenetisc of the 5-HT-3-Receptor

Meeting Abstract

  • corresponding author presenting/speaker Bettina Kollmansberger - Frauenklinik des Universitätsklinkums Erlangen, Deutschland
  • Michael P. Lux - Frauenklinik des Universitätsklinkums Erlangen
  • Kai Beckmann - Frauenklinik des Universitätsklinkums Erlangen
  • Michael Schrauder - Frauenklinik des Universitätsklinkums Erlangen
  • Pamela Strissel - Frauenklinik des Universitätsklinkums Erlangen
  • Reiner Strick - Frauenklinik des Universitätsklinkums Erlangen
  • Matthias W. Beckmann - Frauenklinik des Universitätsklinkums Erlangen
  • Peter A. Fasching - Frauenklinik des Universitätsklinkums Erlangen

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO028

The electronic version of this article is the complete one and can be found online at:

Published: March 20, 2006

© 2006 Kollmansberger et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Introduction: Chemotherapy induced nausea and vomiting (CINV) is a side effect of a chemotherapy. It contributes mainly to the quality of life during the chemotherapy for cancer treatment. Receptor antagonists can reduce but cannot eliminate the rate of patients suffering from CINV. Some patients are refractory to antiemetic therapy. Aim of our study was to find genomic variations which might contribute as a predictor of a higher risk for CINV

Methods: A prospective consecutive cohort of 82 patients with a primary diagnosis of breast cancer was recruited. All patients received an adjuvant chemotherapy with an anthracyclin, 29 patients in addition a taxan. All patients got the same preventive and therapeutic regimen of CINV with 8 mg Ondansetron every 8 hours for the first and second day of the chemotherapy cycle. Additional dexamethason and ondansetron could be administered for symptomatic patients. CINV was documented as well as the intake of additional drugs, food and beverages in a structured patient’s diary. The genome for single nucleotide polymorphisms of the 5-HT3-Receptor and ondansetron metabolizing enzymes was analysed. Statistical analysis included development of a cox-model for the development of CINV after the first infusion of

Results: A total of 53,2% of the patients developed CINV till the end of day 1 of the first chemotherapy cycle. CINV increased 2-3 hours after the infusion of the first cycle and had a maximum 7-8 hours after the start of the first infusion. Highest impact on the prediction of the occurrence of CINV had a polymorphism in the 5-HT3-B-Receptor. 34 patients were heterocygote, 39 a homocygote wildtype genotype for the analyzed SNP. 11 patients had a homocygote mutated genotype. Compared to the wildtype status the heterocygote status had a hazard ratio of 2,2 (p=0,027) for the development of CINV. Other parameters had no significant or clinical relevant impact on the prediction of CINV.

Conclusion: The efficiency of antiemetic treatment seems to depend on pharmacogenetic determinants. The polymorphic variation in the 5-HT-3-B gene seem to contribute partially to the risk for the development of CINV. The analysis of further polymorphisms involved in the pharmacogenetic of preventing and treating nausea and vomitus. Establishing a tool for the prediction of CINV could be the basis for a randomized trial examining the effect of different supportive drugs.